Brief: Prelude Therapeutics Q3 Loss Per Share $0.66
12/11/2021 14:23
Nov 12 (Reuters) - Prelude Therapeutics Inc PRLD.O :
* Q3 LOSS PER SHARE $0.66
* PRELUDE THERAPEUTICS - BELIEVES CURRENT CASH, CASH
EQUIVALENTS &
MARKETABLE SECURITIES WILL BE SUFFICIENT TO FUND OPERATING
EXPENSES INTO 2ND HALF OF 2023
* Q3 EARNINGS PER SHARE VIEW $-0.63 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX5FbQrW
Further company coverage: PRLD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview